Search research articles
Contact Us
Filters
Showing results (421-430 of 519) with videos related to
Page
of 52
Sort By:
Cell Cycle (Georgetown, Tex.)
|
March 10, 2016
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation
Pamela A Lochhead, Jonathan Clark, Lan-Zhen Wang, et al.
Journal of Medicinal Chemistry
|
November 7, 2000
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase
A W White, R Almassy, A H Calvert, et al.
British Journal of Cancer
|
September 1, 1999
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding
N J Curtin, K J Bowman, R N Turner, et al.
British Journal of Clinical Pharmacology
|
February 19, 2002
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide
Huw D Thomas, David J Porter, Imke Bartelink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
A H Calvert, D R Newell, L A Gumbrell, et al.
Haematologica
|
January 19, 2019
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM
Elizabeth C Matheson, Huw Thomas, Marian Case, et al.
Blood
|
September 1, 1985
Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males
S P Kalter, S A Riggs, F Cabanillas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2023
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
A H Calvert, D R Newell, L A Gumbrell, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 17, 2011
Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301
Huw D Thomas, Lan-Zhen Wang, Celine Roche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1993
Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group
D R Newell, A D Pearson, K Balmanno, et al.
Page
of 52
Search research articles
Search
Showing results (421-430 of 519) with videos related to
Sort By:
Page
of 52
Cell Cycle (Georgetown, Tex.)
|
March 10, 2016
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation
Pamela A Lochhead, Jonathan Clark, Lan-Zhen Wang, et al.
Journal of Medicinal Chemistry
|
November 7, 2000
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase
A W White, R Almassy, A H Calvert, et al.
British Journal of Cancer
|
September 1, 1999
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced alpha1-acid glycoprotein binding
N J Curtin, K J Bowman, R N Turner, et al.
British Journal of Clinical Pharmacology
|
February 19, 2002
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide
Huw D Thomas, David J Porter, Imke Bartelink, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 1, 1989
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
A H Calvert, D R Newell, L A Gumbrell, et al.
Haematologica
|
January 19, 2019
Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM
Elizabeth C Matheson, Huw Thomas, Marian Case, et al.
Blood
|
September 1, 1985
Aggressive non-Hodgkin's lymphomas in immunocompromised homosexual males
S P Kalter, S A Riggs, F Cabanillas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 27, 2023
Carboplatin dosage: prospective evaluation of a simple formula based on renal function
A H Calvert, D R Newell, L A Gumbrell, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 17, 2011
Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU6301
Huw D Thomas, Lan-Zhen Wang, Celine Roche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 1993
Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group
D R Newell, A D Pearson, K Balmanno, et al.
Page
of 52